Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 2:17:3053-3060.
doi: 10.2147/NDT.S325062. eCollection 2021.

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment

Silvia Moga  1 , Andreea Teodorescu  1 , Petru Ifteni  1 , Claudia Gavris  1 , Paula-Simina Petric  1
Affiliations

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment

Silvia Moga et al. Neuropsychiatr Dis Treat. .

Abstract

Background: Schizophrenia patients are a population at particular risk of poor outcomes in COVID-19 infection. They have multiple comorbidities that have been identified as risk factors for severe COVID-19: diabetes, hypertension, chronic obstructive respiratory disease, and end-stage renal disease.

Aim: The aim of this research was to evaluate the inflammatory response and in-hospital mortality in schizophrenia patients compared to a control group without mental illness.

Methods: A total of 101 consecutive individuals with schizophrenia tested positive for COVID-19 was compared with 101 individuals without schizophrenia admitted in the same hospital. The number of severe cases and the number of deaths caused by SARS-CoV-2 were evaluated between April 2020 and April 2021.

Results: There were no deaths in the group of patients with schizophrenia. Although the group had a higher number of cases with pulmonary and metabolic comorbidities, in the group with SCZ there were fewer severe cases compared to the control group. The values of some markers of inflammation (CRP and fibrinogen) were significantly lower in SCZ patients. The duration from infection to diagnosis and the start of symptomatic treatment was shorter for the group with SCZ (4.2±3.2 vs 5.3±4.6, p < 0.05).

Conclusion: The main findings of the study were that vulnerable schizophrenia individuals on antipsychotic treatment showed a lower risk of SARS-CoV-2 severe infection and a likely better COVID-19 prognosis in a protective environment. Rapid access to specialists in case of need are factors that have determined the favorable evolution in a group considered high risk. It could be speculated that antipsychotics could play an important role in preventing SARS-CoV-2 severe manifestation and may exert protective effects against detrimental courses of COVID-19.

Keywords: COVID-19; antipsychotics; inflammation; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work

Figures

Figure 1
Figure 1
Age group.
See this image and copyright information in PMC

References

    1. Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull. 2020;46(4):752–757. PMID: 32343342; PMCID: PMC7197583. doi:10.1093/schbul/sbaa051 - DOI - PMC - PubMed
    1. Fond G, Salas S, Pauly V, et al. End-of-life care among patients with schizophrenia and cancer: a population-based cohort study from the French national hospital database. Lancet Public Health. 2019;4(11):e583–e591. PMID: 31677777. doi:10.1016/S2468-2667(19)30187-2 - DOI - PubMed
    1. Melamed OC, Hahn MK, Agarwal SM, Taylor VH, Mulsant BH, Selby P. Physical health among people with serious mental illness in the face of COVID-19: concerns and mitigation strategies. Gen Hosp Psychiatry. 2020;66:30–33. PMID: 32645586; PMCID: PMC7831754. doi:10.1016/j.genhosppsych.2020.06.013 - DOI - PMC - PubMed
    1. Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiatry. 2021;78(4):380–386. doi:10.1001/jamapsychiatry.2020.4442 - DOI - PMC - PubMed
    1. Ifteni P, Dima L, Teodorescu A. Long-acting injectable antipsychotics treatment during COVID-19 pandemic - a new challenge. Schizophr Res. 2020;220:265–266. PMID: 32349886; PMCID: PMC7185008. doi:10.1016/j.schres.2020.04.030 - DOI - PMC - PubMed